Skip to main content
OpenTrials
Completed

NCT Number: NCT01792232

Effects of Co-Exposure to Air Pollution and Allergen

The investigators are investigating the effects of combined exposures to diesel exhaust and allergens on lung function and on the immune system. After exposing individuals to either filtered air or carefully controlled levels of diesel exhaust in our exposure chamber, The investigators will use a procedure called bronchoscopy (whereby a thin, flexible tube is passed down the throat and into the lungs) to place a small amount of allergen directly in the lung. 48h later, the bronchoscopy will be repeated so that samples can be collected from the lungs. After 1mo, the entire procedure will be repeated with the alternate exposure.

Completed

Looking for future studies?

Notify Me

Key information

Age range

19 year–49 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

University of British Columbia

Vancouver, British Columbia, V5Z 1M9, Canada

About this study

  • Purpose/Objective:

To study the effects of diesel exhaust particles on lung function and on allergic responses.

  • Hypotheses:

Hypothesis 1: DE exposure augments systemic oxidative stress from allergen challenge in allergen-sensitized individuals.

Hypothesis 2: DE exposure augments allergen-specific immune response in allergen-challenged airways in sensitized individuals. These responses will be greater in asthmatic individuals than in non-asthmatics.

  • Justification:

The use of diesel engines is increasing because they are more fuel-efficient than gasoline engines. However, diesel engines produce different emissions than gasoline engines. Diesel exhaust is emitted from the tailpipe of both "on-road" diesel engine vehicles (diesel cars, buses and trucks) and "non-road" diesel engines (locomotives, marine vessels and some construction equipment). Diesel exhaust consists of both gaseous and particulate air pollutants. Since people with asthma and allergic diseases appear to be sensitive to air pollution, we would like to know how diesel exhaust (DE) can affects your respiratory and immune systems. We are expecting that any responses that may occur will only be detectable through careful examination of cells and tissues (e.g., bronchoalveolar lavage (fluid from your lungs), blood, urine). Understanding these potentially subtle changes will help us prevent health problems associated with air pollution in the future.

  • Research Method:

This is a blinded crossover experiment between two conditions (DE or filtered air, FA), randomized and counter-balanced to order. Data collection for each condition will be separated by a 4-week washout period.

Following each exposure, The investigators will use bronchoscopy (performed at the Vancouver General Hospital Endoscopy Suite) to deliver a diluent-controlled segmental allergen challenge (SAC). 24 h post-SAC, airway reactivity will be assessed with a methacholine challenge. 48 h post-SAC, bronchoalveolar lavage (BAL), airway brushes and tissue biopsies will be obtained in the same regions for analysis of immune activation. Nasal lavage samples will also be collected to examine responses in the upper airways and blood and urine will be studied to examine systemic responses. Spirometry and methacholine challenge will be used to assess effects on airway function

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age between 19 and 49 years.
  • Non-smoking.
  • Positive skin prick test for at least one of: birch, grass, or dust

Exclusion criteria

  • Using inhaled corticosteroids
  • Pregnant or planning to be pregnant in the next 12 months / Breastfeeding
  • Usage of bronchodilators more than three times per week.
  • Co-morbidities (as assessed by the primary investigator)
  • Taking part in other studies
  • Unwilling to withhold bronchodilator, aspirin, anti-coagulant, antihistamine or decongestant medications or caffeine prior to testing procedures.
  • FEV1(Forced expiratory volume in one second) < 70% predicted.
  • Allergy to lidocaine, fentanyl, midazolam or salbutamol.
  • Unstable asthma (i.e exacerbation in 2 weeks preceding testing)

Treatment and study plan

Allergen

Other

Subject specific allergen is placed in the lungs on day 1 of each triad

Saline

Other

Saline will be placed in the lung on day 1 of each triad

Primary outcomes

  1. Allergen-specific IgE

    Time frame: 48 hours

    BAL IgE specific to the allergen used for allergen challenge will be assessed at 48 hrs, from the BAL, using immunocap assay

Secondary outcomes

  1. Human immune response

    Time frame: 48 hours

    Determine if allergen-induced eosinophilic activation (measured by flow cytometry) and a Th2-type cytokine pattern is augmented by DE (300 µg/m3 inhaled for two hours) exposure.

  2. Oxidative stress

    Time frame: 48 hours

    Establish that bronchial segment allergen-induced oxidative stress (urine 8-isoprostane, measured by ELISA) is augmented by DE (300 µg/m3 inhaled for two hours) exposure.

  3. Airway reactivity

    Time frame: 48 hours

    Determine if airway reactivity (measured by PC20 methacholine challenge) is augmented by DE (300 µg/m3 inhaled for two hours) exposure.

Sponsors and collaborators

Lead sponsor

University of British Columbia

Other

Registry information

Official study title

Effect of Exposure to Allergens and Air Pollution on Lung Function and Immunity

Important dates

Study start
2011
Primary completion
2013
Study completion
2013
First posted
Feb 15, 2013
Registry last updated
Sep 29, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.